Skip to content

Radiopharm Theranostics Limited

RADX RDPTF

CIK 0001949257

← back to feed
Revenue (TTM)
$3.63M
FY Jun 2025
Net Income (TTM)
−$38.34M
+20.0% YoY FY Jun 2025
EPS Diluted (TTM)
−$1.76
+85.8% YoY FY Jun 2025
Gross Margin
1.1%
FY Jun 2025
Operating Margin
-1,050.6%
FY Jun 2025
Net Margin
-1,055.3%
FY Jun 2025
Free Cash Flow (TTM)
—
FY Jun 2025
Cash
$29.12M
FY Jun 2025
Total Debt
—
FY Jun 2025
Shares Outstanding
2.36B sh
FY Jun 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings